CTRI/2022/09/046057CompletedNot Applicable
An Open-Label, Randomized, Single Oral Dose, Two-Period, Cross-Over Trial to Assess the Bioequivalence of Dydrogesterone 10mg tablets (Test Drug) of Medethix Inc. in Comparison with Tab. Duphaston (Dydrogesterone) 10mg tablets (Reference Drug) of Abbott Labs. in Healthy FemaleSubjects Under Fasting Conditions.
Medethix Inc1 site in 1 country28 target enrollmentStarted: March 10, 2022Last updated:
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 28
- Locations
- 1
- Primary Endpoint
- Bioavailability of the test product Dydrogesterone 10 mg is compared against the innovator Duphaston 10mg.
Study Overview
Brief Summary
Objectives:
- To compare and evaluate the oral bioavailability of Dydrogesterone 10mg tablets (Test Drug) Of Medethix Inc. In Comparison with Duphaston (Dydrogesterone) 10mg tablets (Reference Drug) Of Abbott Labs. in Healthy Female Subjects Under Fasting Conditions in healthy, adult, human subjects under fasting conditions.
- To monitor the safety of the subjects
Study Design:
- An open label, randomized, two-period, two-treatment, two-sequence, crossover, balanced, single dose oral bioequivalence study.
Study Duration:
- Considering the 7 days washout period, expected study duration of clinical part is 17 days from the day of check-in of first period.
Study Design
- Study Type
- Interventional
- Allocation
- Computer generated randomization
- Masking
- Open Label
Eligibility Criteria
- Ages
- 18.00 Year(s) to 45.00 Year(s) (—)
- Sex
- Female
Inclusion Criteria
- •Volunteers with age of 18 to 45 years old, both inclusive.
- •Non-pregnant, non-lactating female.
- •a.Female of childbearing potential must have a negative serum beta human chorionic gonadotropin pregnancy test performed within 28 days prior to first dosing day & prior to check-in of each period.
- •They must be using an acceptable form of contraception.
- •b.For female of childbearing potential, acceptable forms of contraception include any one of the following: •Non hormonal intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study Barrier methods containing or used in conjunction with a spermicidal agent Surgical sterilization Practicing sexual abstinence throughout the course of the study.
- •Female will not be considered of childbearing potential if one of the following is reported and documented on the medical history: Postmenopausal with spontaneous amenorrhea for at least one year, or Bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months, or Total hysterectomy and an absence of bleeding for at least 3 months.
- •18.5 to 30.0 weight in kg /m2, both inclusive Able to communicate effectively with study personnel.
- •Able to give written informed consent to participate in the study.
- •All volunteers must be judged by the principal or sub-investigator or physician as normal and healthy during a pre-study safety assessment performed within 28 days of the first dose of study medication which will include: A physical examination with no clinically significant finding.
- •Results within normal limits or clinically non-significant for the following tests: Hematology, Blood Chemistry, Urinalysis, Immunological Tests, Serum (β-HCG) Pregnancy Test (for female of child bearing potential) •Additional tests and/or examinations may be performed, if necessary, based on Principal Investigator discretion.
Exclusion Criteria
- •History of allergic responses to Dydrogesterone or other related drugs, or any of its formulation ingredients.
- •Known or suspected progestogen dependant neoplasms 3) Volunteer with undiagnosed irregular vaginal bleeding.
- •Volunteer with hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption 5) Have significant diseases or clinically significant abnormal findings during screening 6) Any disease or condition like diabetes, psychosis, adrenal insufficiency, thyrotoxicosis, seizures or others which might compromise the haemopoietic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system, endocrine or any other body system.
- •Use of any hormone replacement therapy within 3 months prior to the first dose of study medication.
- •Use of enzyme-modifying drugs within 30 days prior to the first dose of study medication.
- •Use of estrogens 30 days prior to the first dose of study medication and throughout the study.
- •History or evidence of drug dependence or of alcoholism or of moderate alcohol use.
- •Smokers who smoke 10 or more cigarettes per day or 20 or more biddies per day or those who cannot refrain from smoking during the study period.
- •History of difficulty with donating blood or difficulty in accessibility of veins.
- •A positive hepatitis screen (includes subtypes B and C).
- •A positive test result for HV antibody and/ or syphilis (RPR/VDRL).
- •Volunteers who have received a known investigational drug within ten elimination half-life of the administered drug prior to the first dose of study medication or have donated blood or loss of blood 50 mL to 100 mL within 30 days or 101 mL to 200 mL within 60 days or >200 mL within 90 days (excluding volume drawn at screening for this study) prior to first dose of study medication, whichever is greater.
- •Intolerance to venipuncture.
- •Any food allergy, intolerance, restriction or special diet that, in the opinion of the Principal Investigator or Sub-Investigator, could contraindicate the volunteer participation in this study.
Outcomes
Primary Outcomes
Bioavailability of the test product Dydrogesterone 10 mg is compared against the innovator Duphaston 10mg.
Time Frame: 17 days
Secondary Outcomes
- AUC, Cmax and Tmax(Between Day 1 and Day 17 across 2 periods)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
Bioequivalence Study of Sertraline Hydrochloride Tablets 100 mg in Fed ConditionsHealthyNCT01267383Dr. Reddy's Laboratories Limited32
Completed
Phase 1
Bioequivalence Study of Sertraline Hydrochloride Tablets 100 mg Under Fasting ConditionsHealthyNCT01267396Dr. Reddy's Laboratories Limited32
Completed
Phase 1
Bioequivalence Study of Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Under Fed ConditionsHealthyNCT01645423Dr. Reddy's Laboratories Limited77
Completed
Phase 1
Bioequivalence Study of Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Under Fasting ConditionsHealthyNCT01645449Dr. Reddy's Laboratories Limited77
Completed
Phase 1
A Study to Evaluate the Bioavailability of Two Specifications of Oral Deuremidevir Hydrobromide for SuspensionHealthy ParticipantsNCT06749236Vigonvita Life Sciences18